Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug BGB-24714 tested in early trial for solid tumors

NCT ID NCT05381909

Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called BGB-24714, which is designed to help cancer cells die. It was given alone or with chemotherapy to 157 adults with advanced solid tumors that had spread or could not be removed. The main goal was to find a safe dose and see how well people tolerated the treatment. The study was terminated early, so full results may not be available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BGB-24714 (a drug that helps cancer cells die), given with or without chemotherapy drugs like paclitaxel, carboplatin, or docetaxel
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early phase 1 trial, so the main goal is just to find a safe dose. It is too soon to know if the drug will actually shrink tumors or help patients live longer. The trial was also terminated early, so results may be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

157 people

The number who actually took part.

Started

Jul 2022

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Eligibility Criteria : 1. Participants must sign a written informed consent form (ICF); and agree to comply with study requirement 2. Phase 1a (Dose Escalation): Part A, A-CN, and B: Participants with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumor previously treated with standard systemic therapy or for whom treatment is not available or not tolerated Note: Only Chinese participants will be eligible for Part A-CN. Part C: Participant has histologically or cytologically confirmed, locally advanced, unresectable Stage III Non-small cell lung cancer (NSCLC) suitable for definitive chemoradiotherapy (CRT) Part D: Participant with locally advanced, histologically confirmed inoperable esophageal squamous cell carcinoma (ESCC) suitable for definitive CRT Phase 1b (Dose Expansion): Participants with histologically or cytologically confirmed solid tumors of selected types previously treated with standard therapy. 3. Participants must be able to provide formalin-fixed paraffin embedded (FFPE) tumor tissue sample. 4. Phase 1a Part A, A-CN, B and Phase 1b: ≥ 1 measurable lesion per Response evaluation criteria in solid tumors (RECIST) v1.1 5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1 Key Exclusion Criteria: 1. Active leptomeningeal disease or uncontrolled, untreated brain metastasis. 2. Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent 3. Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before the first dose of study drug(s). 4. Clinically significant infection requiring systemic therapy ≤ 14 days before the first dose of study drug(s). 5. Prior exposure to agents with second mitochondria-derived activator of caspases (SMAC) mimetics, or other Inhibitors of apoptosis proteins (IAPs) antagonists. NOTE: Other protocol defined inclusion/exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumor, adult

Contacts and locations

Locations

  • Asan Medical Center

    SongpaGu, Seoul Teugbyeolsi, 05505, South Korea

  • Auckland City Hospital

    Auckland, 1023, New Zealand

  • Austin Health

    Heidelberg, Victoria, VIC 3084, Australia

  • Avera Cancer Institute

    Sioux Falls, South Dakota, 57105-2108, United States

  • Banner Md Anderson Cancer Center

    Gilbert, Arizona, 85234-2165, United States

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan, 48201-2013, United States

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, 400030, China

  • Florida Cancer Specialist (Scri) Sarasota

    Sarasota, Florida, 34232, United States

  • Gachon University Gil Medical Center

    NamdongGu, Incheon Gwang'yeogsi, 21565, South Korea

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601-1915, United States

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Icon Cancer Centre South Brisbane

    South Brisbane, Queensland, QLD 4101, Australia

  • Intermountain Healthcare

    Salt Lake City, Utah, 84143, United States

  • Mary Crowley Cancer Research

    Dallas, Texas, 75230, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • National Cancer Center (Korea)

    IlsandongGu GoyangSi, Gyeonggi-do, 10408, South Korea

  • Next Virginia

    Fairfax, Virginia, 22031, United States

  • Northern Beaches Hospital

    Frenchs Forest, New South Wales, NSW 2086, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, VIC 3000, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, QLD 4102, Australia

  • Samsung Medical Center

    GangnamGu, Seoul Teugbyeolsi, 06351, South Korea

  • Sanford Cancer Center

    Sioux Falls, South Dakota, 57104-4663, United States

  • Scri Florida Cancer Specialist East

    West Palm Beach, Florida, 33401-3406, United States

  • Scri Florida Cancer Specialists North

    St. Petersburg, Florida, 33705-1449, United States

  • Severance Hospital Yonsei University Health System

    SeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea

  • Shandong Cancer Hospital

    Jinan, Shandong, 250117, China

  • Shandong Provincial Hospital

    Jinan, Shandong, 250021, China

  • Sunshine Hospital

    St Albans, Victoria, VIC 3021, Australia

  • Tennessee Oncology, Pllc Nashville

    Nashville, Tennessee, 37203, United States

  • The University of Texas Md Anderson Cancer Center (Department Gi Medical Oncology)

    Houston, Texas, 77030-4000, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390-7208, United States

  • University of Washington

    Seattle, Washington, 98195, United States

  • Upmc Hillman Cancer Center(Univ of Pittsburgh)

    Pittsburgh, Pennsylvania, 15232-1309, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.